U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H21N3O5
Molecular Weight 311.3336
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LEONURINE

SMILES

COC1=CC(=CC(OC)=C1O)C(=O)OCCCCNC(N)=N

InChI

InChIKey=WNGSUWLDMZFYNZ-UHFFFAOYSA-N
InChI=1S/C14H21N3O5/c1-20-10-7-9(8-11(21-2)12(10)18)13(19)22-6-4-3-5-17-14(15)16/h7-8,18H,3-6H2,1-2H3,(H4,15,16,17)

HIDE SMILES / InChI

Molecular Formula C14H21N3O5
Molecular Weight 311.3336
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Leonurine (LN) is a natural alkaloid extracted from Herba leonuri which is used in Chinese traditional medicine and possesses anti-inflammatory properties. Leonurine has potential as a therapeutic agent for rheumatoid arthritis and might be a promising therapeutic compound to treat osteoclast-related diseases, such as osteoporosis. These effects are achieved through the inhibition of NF-κB and mitogen-activated protein kinase pathways. In addition, it was found that leonurine protects BBB integrity by regulating the HDAC4/NOX4/MMP-9 tight junction pathway and could therfeore represent a new class of potential drugs against the acute onset of ischemic stroke. In experiments on mice with adenomyosis leonurine attenuated generalized hyperalgesia, however, the mechanism responsible for alleviating pain was not readily apparent.

CNS Activity

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
Unknown
Primary
Unknown
Primary
Unknown
Preventing
Unknown

PubMed

Patents

Sample Use Guides

In Vivo Use Guide
mice with adenomyosis: group 1 received a low-dose (30 mg/kg body weight) leonurine treatment; group 2 received a high-dose (60 mg/kg body weight) leonurine
Route of Administration: Oral
In Vitro Use Guide
Leonurine could obviously attenuate the spontaneous excitatory postsynaptic current amplitude and frequency on pyramidal neurons. In in vitro study, there were control group, OGD group, OGD+ 100µM leonurin group, and OGD+ 10µM donepezil group.
Substance Class Chemical
Record UNII
09Q5W34QDA
Record Status Validated (UNII)
Record Version